Veracyte Stock Price, News & Analysis (NASDAQ:VCYT)

$5.76 +0.07 (+1.23 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$5.76
Today's Range$5.53 - $5.83
52-Week Range$5.23 - $9.80
Volume76,567 shs
Average Volume111,494 shs
Market Capitalization$193.69 million
P/E Ratio-7.11
Dividend YieldN/A
Beta1.63

About Veracyte (NASDAQ:VCYT)

Veracyte logoVeracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company’s commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis.

Receive VCYT News and Ratings via Email

Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Diagnostics & Testing
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VCYT
CUSIPN/A
Phone650-243-6300

Debt

Debt-to-Equity Ratio0.59%
Current Ratio5.19%
Quick Ratio4.86%

Price-To-Earnings

Trailing P/E Ratio-7.11102332069974
Forward P/E Ratio-6.62
P/E GrowthN/A

Sales & Book Value

Annual Sales$65.08 million
Price / Sales3.01
Cash FlowN/A
Price / CashN/A
Book Value$1.81 per share
Price / Book3.18

Profitability

Trailing EPS($0.81)
Net Income$-31,350,000.00
Net Margins-38.19%
Return on Equity-52.99%
Return on Assets-29.50%

Miscellaneous

Employees216
Outstanding Shares34,040,000

Veracyte (NASDAQ:VCYT) Frequently Asked Questions

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

How were Veracyte's earnings last quarter?

Veracyte Inc (NASDAQ:VCYT) released its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.21) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.21). The biotechnology company had revenue of $17.50 million for the quarter, compared to the consensus estimate of $19.54 million. Veracyte had a negative return on equity of 52.99% and a negative net margin of 38.19%. The company's quarterly revenue was down 5.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.20) earnings per share. View Veracyte's Earnings History.

Where is Veracyte's stock going? Where will Veracyte's stock price be in 2018?

5 brokers have issued 1-year price objectives for Veracyte's shares. Their predictions range from $9.00 to $15.00. On average, they expect Veracyte's share price to reach $12.50 in the next twelve months. View Analyst Ratings for Veracyte.

Who are some of Veracyte's key competitors?

Who are Veracyte's key executives?

Veracyte's management team includes the folowing people:

  • Bonnie H. Anderson, Chairman of the Board, Chief Executive Officer (Age 58)
  • Christopher M. Hall, President, Chief Operating Officer (Age 48)
  • Keith S. Kennedy, Chief Financial Officer (Age 47)
  • Julie A. Brooks, General Counsel, Secretary (Age 71)
  • John W. Hanna, Chief Commercial Officer
  • John L. Bishop, Lead Independent Director (Age 72)
  • Fred E. Cohen Ph.D. M.D., Independent Director (Age 60)
  • Karin Eastham CPA, Independent Director (Age 67)
  • Robert S. Epstein M.D., Independent Director (Age 62)
  • Kevin K. Gordon, Independent Director (Age 54)

Who owns Veracyte stock?

Veracyte's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.41%), ARK Investment Management LLC (4.12%), Stonepine Capital Management LLC (3.63%), Millennium Management LLC (2.29%), Broadfin Capital LLC (2.19%) and First Manhattan Co. (0.80%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones and Jesse I Treu. View Institutional Ownership Trends for Veracyte.

Who sold Veracyte stock? Who is selling Veracyte stock?

Veracyte's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Spark Investment Management LLC and Two Sigma Investments LP. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones and Jesse I Treu. View Insider Buying and Selling for Veracyte.

Who bought Veracyte stock? Who is buying Veracyte stock?

Veracyte's stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Stonepine Capital Management LLC, BlackRock Inc., First Manhattan Co., Algert Global LLC, Essex Investment Management Co. LLC, Millennium Management LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Veracyte.

How do I buy Veracyte stock?

Shares of Veracyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Veracyte's stock price today?

One share of Veracyte stock can currently be purchased for approximately $5.76.

How big of a company is Veracyte?

Veracyte has a market capitalization of $193.69 million and generates $65.08 million in revenue each year. The biotechnology company earns $-31,350,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Veracyte employs 216 workers across the globe.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]


MarketBeat Community Rating for Veracyte (VCYT)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  339
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Veracyte (NASDAQ:VCYT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.602.603.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.50$12.50$12.50$13.00
Price Target Upside: 95.31% upside95.31% upside95.31% upside59.90% upside

Veracyte (NASDAQ:VCYT) Consensus Price Target History

Price Target History for Veracyte (NASDAQ:VCYT)

Veracyte (NASDAQ:VCYT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017BTIG ResearchSet Price TargetBuy$13.00N/AView Rating Details
11/7/2017Leerink SwannLower Price TargetOutperform$12.00 -> $9.00N/AView Rating Details
11/7/2017Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
11/7/2017Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
5/18/2017Cantor FitzgeraldSet Price TargetBuy$13.00LowView Rating Details
10/18/2016William BlairReiterated RatingOutperformN/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Veracyte (NASDAQ:VCYT) Earnings History and Estimates Chart

Earnings by Quarter for Veracyte (NASDAQ:VCYT)

Veracyte (NASDAQ VCYT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.21)($0.21)$19.54 million$17.50 millionViewN/AView Earnings Details
7/31/2017Q2 2017($0.25)($0.22)$18.32 million$18.40 millionViewN/AView Earnings Details
5/3/2017Q1 2017($0.24)($0.24)$18.09 million$16.43 millionViewListenView Earnings Details
3/1/2017Q416($0.26)($0.14)$17.49 million$18.30 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.20)$15.76 million$18.60 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.40)$14.80 million$14.68 millionViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.36)$13.08 million$13.55 millionViewN/AView Earnings Details
3/10/2016Q415($0.30)($0.29)$14.45 million$14.04 millionViewListenView Earnings Details
11/5/2015Q315($0.33)($0.32)$12.72 million$12.33 millionViewListenView Earnings Details
8/13/2015Q215($0.31)($0.35)$12.23 million$11.90 millionViewListenView Earnings Details
5/14/2015Q115($0.37)($0.34)$10.83 million$11.20 millionViewListenView Earnings Details
3/19/2015Q414($0.33)($0.36)$11.83 million$12.20 millionViewN/AView Earnings Details
11/13/2014Q314($0.35)($0.37)$9.67 million$9.80 millionViewN/AView Earnings Details
8/13/2014Q214($0.33)($0.31)$9.36 million$8.70 millionViewN/AView Earnings Details
5/8/2014Q114($0.31)($0.32)$7.19 million$7.50 millionViewN/AView Earnings Details
3/18/2014Q4($0.38)($0.42)$6.43 million$6.84 millionViewListenView Earnings Details
11/25/2013Q313($6.59)$3.20 million$5.60 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Veracyte (NASDAQ:VCYT) Earnings Estimates

2018 EPS Consensus Estimate: ($0.64)
2019 EPS Consensus Estimate: ($0.33)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.19)($0.18)($0.19)
Q2 20182($0.17)($0.15)($0.16)
Q3 20182($0.16)($0.14)($0.15)
Q4 20182($0.15)($0.13)($0.14)
Q1 20191($0.13)($0.13)($0.13)
Q2 20191($0.10)($0.10)($0.10)
Q3 20191($0.06)($0.06)($0.06)
Q4 20191($0.04)($0.04)($0.04)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Veracyte (NASDAQ:VCYT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Veracyte (NASDAQ VCYT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.40%
Institutional Ownership Percentage: 74.76%
Insider Trades by Quarter for Veracyte (NASDAQ:VCYT)
Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Veracyte (NASDAQ VCYT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/20/2017Bonnie H AndersonChairmanSell16,000$9.41$150,560.0016,000View SEC Filing  
10/18/2017Bonnie H AndersonCEOSell6,000$9.09$54,540.0016,000View SEC Filing  
10/2/2017Christopher M HallInsiderSell20,000$9.00$180,000.00View SEC Filing  
9/25/2017Bonnie H AndersonChairmanSell6,000$8.44$50,640.0016,000View SEC Filing  
8/28/2017Evan/ Fa JonesDirectorSell22,500$7.81$175,725.00View SEC Filing  
8/24/2017Evan/ Fa JonesDirectorSell40,000$7.88$315,200.00View SEC Filing  
8/23/2017Evan/ Fa JonesDirectorSell20,000$7.92$158,400.00View SEC Filing  
5/16/2017Jesse I TreuDirectorSell2,226$8.08$17,986.081,642View SEC Filing  
3/21/2017Bonnie H AndersonChairmanSell5,000$9.09$45,450.0015,000View SEC Filing  
6/3/2016Bonnie H AndersonCEOBuy5,000$5.40$27,000.007,500View SEC Filing  
6/1/2016Bonnie H AndersonCEOBuy5,000$5.46$27,300.002,500View SEC Filing  
5/31/2016Bonnie H AndersonCEOBuy2,500$5.46$13,650.002,500View SEC Filing  
11/25/2015Evan/ Fa JonesDirectorSell7,896$7.23$57,088.08View SEC Filing  
11/24/2015Evan/ Fa JonesDirectorSell7,104$7.20$51,148.80View SEC Filing  
7/22/2015Christopher M HallCOOSell2,500$11.85$29,625.00View SEC Filing  
6/26/2015Shelly D GuyerCFOSell1,000$12.08$12,080.00View SEC Filing  
9/10/2014Christopher M HallInsiderSell1,000$12.29$12,290.00View SEC Filing  
9/9/2014Evan/ Fa JonesDirectorSell27,304$12.60$344,030.40View SEC Filing  
8/18/2014Christopher M HallInsiderSell1,000$12.92$12,920.00View SEC Filing  
7/29/2014Julie BrooksEVPBuy1,122$14.69$16,482.18View SEC Filing  
7/28/2014Julie BrooksEVPBuy1,000$14.71$14,710.00View SEC Filing  
7/22/2014Julie BrooksVPBuy2,000$14.18$28,360.00View SEC Filing  
7/21/2014Julie BrooksVPBuy1,000$14.00$14,000.00View SEC Filing  
7/10/2014Christopher M HallInsiderSell3,000$14.92$44,760.00View SEC Filing  
6/27/2014Bonnie H AndersonCEOSell1,000$17.95$17,950.00View SEC Filing  
6/23/2014Bonnie H AndersonCEOSell4,000$16.45$65,800.00View SEC Filing  
6/23/2014Christopher M HallInsiderSell2,000$16.95$33,900.00View SEC Filing  
6/20/2014Shelly D GuyerCFOSell1,250$16.04$20,050.00View SEC Filing  
6/19/2014Christopher M HallInsiderSell3,000$14.99$44,970.00View SEC Filing  
6/12/2014Evan/ Fa JonesDirectorSell16,650$15.07$250,915.50View SEC Filing  
6/9/2014Evan/ Fa JonesDirectorSell22,870$14.57$333,215.90View SEC Filing  
6/5/2014Evan/ Fa JonesDirectorSell28,248$14.33$404,793.84View SEC Filing  
5/30/2014Evan/ Fa JonesDirectorSell23,882$15.33$366,111.06View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Veracyte (NASDAQ VCYT) News Headlines

Source:
DateHeadline
Veracyte Inc (VCYT) Receives Consensus Rating of "Hold" from BrokeragesVeracyte Inc (VCYT) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 21 at 9:52 AM
Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2017 Financial Results on Tuesday, February 27, 2018Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2017 Financial Results on Tuesday, February 27, 2018
finance.yahoo.com - February 12 at 9:06 AM
Veracyte (VCYT) Lowered to Strong Sell at ValuEngineVeracyte (VCYT) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - February 4 at 9:02 AM
Veracyte to Present at LEERINK Partners 7th Annual Global Healthcare ConferenceVeracyte to Present at LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - January 31 at 9:23 AM
Brokers Set Expectations for Veracyte Incs Q1 2019 Earnings (VCYT)Brokers Set Expectations for Veracyte Inc's Q1 2019 Earnings (VCYT)
www.americanbankingnews.com - January 29 at 7:30 AM
Veracyte Inc (VCYT) Expected to Post Quarterly Sales of $18.84 MillionVeracyte Inc (VCYT) Expected to Post Quarterly Sales of $18.84 Million
www.americanbankingnews.com - January 28 at 6:26 AM
Veracyte Inc (VCYT) Given Consensus Recommendation of "Hold" by AnalystsVeracyte Inc (VCYT) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - January 27 at 10:32 AM
Veracyte Announces 100,000th Afirma Test Performed to Reduce Unnecessary Surgeries in Thyroid Cancer DiagnosisVeracyte Announces 100,000th Afirma Test Performed to Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis
finance.yahoo.com - January 25 at 4:25 PM
Veracyte’s Chief Science and Medical Officer to Present at The Precision Medicine World ConferenceVeracyte’s Chief Science and Medical Officer to Present at The Precision Medicine World Conference
finance.yahoo.com - January 19 at 4:52 PM
Veracyte Announces Publication of Results from Patient Survey Quantifying the Challenges in Diagnosing Interstitial Lung DiseaseVeracyte Announces Publication of Results from Patient Survey Quantifying the Challenges in Diagnosing Interstitial Lung Disease
finance.yahoo.com - January 18 at 11:35 AM
-$0.20 Earnings Per Share Expected for Veracyte, Inc. (VCYT) This Quarter-$0.20 Earnings Per Share Expected for Veracyte, Inc. (VCYT) This Quarter
www.americanbankingnews.com - January 8 at 11:06 PM
Veracyte Announces Strategic Realignment and New Appointments to Advance Commercial GrowthVeracyte Announces Strategic Realignment and New Appointments to Advance Commercial Growth
finance.yahoo.com - January 8 at 10:40 AM
Veracyte, Inc. (VCYT) Receives Average Rating of "Hold" from BrokeragesVeracyte, Inc. (VCYT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 2 at 9:58 AM
$18.84 Million in Sales Expected for Veracyte, Inc. (VCYT) This Quarter$18.84 Million in Sales Expected for Veracyte, Inc. (VCYT) This Quarter
www.americanbankingnews.com - December 25 at 10:32 AM
Veracyte, Inc. (VCYT) Expected to Post Earnings of -$0.20 Per ShareVeracyte, Inc. (VCYT) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - December 23 at 3:30 PM
InVitae (NVTA) and Veracyte (VCYT) Financial ContrastInVitae (NVTA) and Veracyte (VCYT) Financial Contrast
www.americanbankingnews.com - December 15 at 9:46 AM
Are Options Traders Betting on a Big Move in Veracyte (VCYT) Stock?Are Options Traders Betting on a Big Move in Veracyte (VCYT) Stock?
finance.yahoo.com - December 14 at 10:37 AM
Analyzing Veracyte (VCYT) & Digiliti Money Group (DGLT)Analyzing Veracyte (VCYT) & Digiliti Money Group (DGLT)
www.americanbankingnews.com - December 13 at 3:54 PM
ETFs with exposure to Veracyte, Inc. : December 11, 2017ETFs with exposure to Veracyte, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 4:37 PM
Veracyte, Inc. (VCYT) Given Average Recommendation of "Hold" by AnalystsVeracyte, Inc. (VCYT) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 8 at 9:52 AM
Veracyte, Inc. (VCYT) Expected to Post Quarterly Sales of $18.84 MillionVeracyte, Inc. (VCYT) Expected to Post Quarterly Sales of $18.84 Million
www.americanbankingnews.com - December 7 at 8:00 AM
 Analysts Expect Veracyte, Inc. (VCYT) to Post -$0.20 Earnings Per Share Analysts Expect Veracyte, Inc. (VCYT) to Post -$0.20 Earnings Per Share
www.americanbankingnews.com - December 5 at 9:26 PM
ETFs with exposure to Veracyte, Inc. : December 1, 2017ETFs with exposure to Veracyte, Inc. : December 1, 2017
finance.yahoo.com - December 1 at 5:44 PM
Veracyte, Inc. :VCYT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017Veracyte, Inc. :VCYT-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
finance.yahoo.com - November 30 at 11:07 AM
Veracyte Announces Publication of Data Confirming Analytical Validity of Envisia Genomic Classifier for Use in IPF DiagnosisVeracyte Announces Publication of Data Confirming Analytical Validity of Envisia Genomic Classifier for Use in IPF Diagnosis
finance.yahoo.com - November 28 at 11:33 AM
BTIG Research Analysts Give Veracyte, Inc. (VCYT) a $13.00 Price TargetBTIG Research Analysts Give Veracyte, Inc. (VCYT) a $13.00 Price Target
www.americanbankingnews.com - November 21 at 8:14 PM
Financial Survey: Invitae Corporation (NVTA) and Veracyte (VCYT)Financial Survey: Invitae Corporation (NVTA) and Veracyte (VCYT)
www.americanbankingnews.com - November 18 at 5:42 PM
Veracyte to Present at the Piper Jaffray 29th Annual Healthcare ConferenceVeracyte to Present at the Piper Jaffray 29th Annual Healthcare Conference
finance.yahoo.com - November 16 at 5:08 AM
Veracyte, Inc. (VCYT) Receives Average Recommendation of "Hold" from BrokeragesVeracyte, Inc. (VCYT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 13 at 10:54 AM
Veracyte Announces New Clinical Utility Data Suggesting Envisia Genomic Classifier Enables as Confident a Diagnosis in IPF as Surgical PathologyVeracyte Announces New Clinical Utility Data Suggesting Envisia Genomic Classifier Enables as Confident a Diagnosis in IPF as Surgical Pathology
finance.yahoo.com - November 12 at 1:06 PM
Veracyte, Inc. (VCYT) Stock Rating Upgraded by Zacks Investment ResearchVeracyte, Inc. (VCYT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 10 at 8:37 AM
FY2017 Earnings Forecast for Veracyte, Inc. Issued By Leerink Swann (VCYT)FY2017 Earnings Forecast for Veracyte, Inc. Issued By Leerink Swann (VCYT)
www.americanbankingnews.com - November 9 at 6:22 AM
Veracyte, Inc. (VCYT) Given New $9.00 Price Target at Leerink SwannVeracyte, Inc. (VCYT) Given New $9.00 Price Target at Leerink Swann
www.americanbankingnews.com - November 7 at 2:30 PM
Veracyte Announces Third Quarter 2017 Financial ResultsVeracyte Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 12:59 PM
Edited Transcript of VCYT earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of VCYT earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 12:58 PM
Veracyte, Inc. (VCYT) Posts  Earnings ResultsVeracyte, Inc. (VCYT) Posts Earnings Results
www.americanbankingnews.com - November 7 at 9:06 AM
Veracyte, Inc. (VCYT) Stock Rating Lowered by Janney Montgomery ScottVeracyte, Inc. (VCYT) Stock Rating Lowered by Janney Montgomery Scott
www.americanbankingnews.com - November 7 at 8:33 AM
CORRECTING and REPLACING Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer DiagnosisCORRECTING and REPLACING Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
finance.yahoo.com - November 4 at 6:08 AM
Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics ForumVeracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
finance.yahoo.com - November 2 at 10:51 AM
Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer DiagnosisVeracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
finance.yahoo.com - November 1 at 10:23 AM
Veracyte, Inc. (VCYT) Expected to Announce Quarterly Sales of $19.96 MillionVeracyte, Inc. (VCYT) Expected to Announce Quarterly Sales of $19.96 Million
www.americanbankingnews.com - October 30 at 8:23 AM
 Analysts Anticipate Veracyte, Inc. (VCYT) Will Post Earnings of -$0.21 Per Share Analysts Anticipate Veracyte, Inc. (VCYT) Will Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - October 28 at 7:34 AM
Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results on Monday, November 6, 2017Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results on Monday, November 6, 2017
finance.yahoo.com - October 26 at 12:04 PM
Veracyte, Inc. (VCYT) Scheduled to Post Earnings on WednesdayVeracyte, Inc. (VCYT) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - October 25 at 3:48 AM
Veracyte Announces New Data Highlighting Performance of the Afirma GSC Ensemble Machine Learning Algorithms in Challenging Thyroid Cancer Subtypes to Be Presented at ATAVeracyte Announces New Data Highlighting Performance of the Afirma GSC Ensemble Machine Learning Algorithms in Challenging Thyroid Cancer Subtypes to Be Presented at ATA
finance.yahoo.com - October 22 at 7:46 AM
Veracyte, Inc. (VCYT) CEO Bonnie H. Anderson Sells 6,000 SharesVeracyte, Inc. (VCYT) CEO Bonnie H. Anderson Sells 6,000 Shares
www.americanbankingnews.com - October 20 at 7:44 PM
Bonnie H. Anderson Sells 16,000 Shares of Veracyte, Inc. (VCYT) StockBonnie H. Anderson Sells 16,000 Shares of Veracyte, Inc. (VCYT) Stock
www.americanbankingnews.com - October 20 at 7:44 PM
Veracyte Announces Presentation of New Data Validating Accuracy of BRAF V600E and Parathyroid Tissue Classifiers at ATA Annual MeetingVeracyte Announces Presentation of New Data Validating Accuracy of BRAF V600E and Parathyroid Tissue Classifiers at ATA Annual Meeting
finance.yahoo.com - October 20 at 4:20 PM
Veracyte (VCYT) Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHESTVeracyte (VCYT) Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHEST
www.streetinsider.com - October 20 at 9:52 AM
Veracyte Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHEST Annual Meeting 2017Veracyte Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHEST Annual Meeting 2017
finance.yahoo.com - October 20 at 9:52 AM

SEC Filings

Veracyte (NASDAQ:VCYT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Veracyte (NASDAQ:VCYT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Veracyte (NASDAQ VCYT) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.